Literature DB >> 7810710

CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins.

R Vetter1, H Rupp.   

Abstract

To characterize the effect of an altered substrate utilization for cardiac sarcoplasmic reticulum (SR) Ca2+ transport, normotensive rats were treated for 5 wk with 15 mg.kg-1.day-1 enantiomeric etomoxir, which inhibits mitochondrial carnitine palmitoyltransferase-1 (CPT-1) and fatty acid synthesis. Ca2+ uptake rates of left and right ventricular homogenates were differentially (P < 0.05, two-way analysis of variance) increased by 38 and 13%, respectively. Increased (P < 0.05) transport rates were also observed in the presence of ryanodine. The differences were considerably reduced in the protein kinase A-stimulated state. The levels of phosphorylated phospholamban (PLB) and troponin I as well as immunoreactive PLB were not affected. By contrast, phosphoenzyme levels (E-P) of the SR Ca2+ pump were increased in left ventricular (LV) homogenates. Values of LV E-P and Ca2+ uptake were linearly correlated (P < 0.05) with the myosin V1 proportions in control (31.7 +/- 1.8% V1) and treated (58.3 +/- 2.5% V1) rats. Thus in the left ventricle the metabolic influences have a coordinated action on two distinct proteins involved in relaxation or contraction. The chamber-specific differences in SR function suggest a more pronounced effect of etomoxir in functional states characterized by a reduced Ca2+ transport rate and myosin V1 proportion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810710     DOI: 10.1152/ajpheart.1994.267.6.H2091

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies.

Authors:  Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-02       Impact factor: 15.534

2.  Influence of different culture conditions on sarcoplasmic reticular calcium transport in isolated neonatal rat cardiomyocytes.

Authors:  R Vetter; M Kott; W Schulze; H Rupp
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

3.  The effect of Mg2+ on cardiac muscle function: Is CaATP the substrate for priming myofibril cross-bridge formation and Ca2+ reuptake by the sarcoplasmic reticulum?

Authors:  G A Smith; J I Vandenberg; N S Freestone; H B Dixon
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

Review 4.  Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective.

Authors:  Andrew A Wolff; Heschi H Rotmensch; William C Stanley; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 5.  Energy metabolism in the normal and failing heart: potential for therapeutic interventions.

Authors:  William C Stanley; Margaret P Chandler
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

6.  Modification of left ventricular hypertrophy by chronic etomixir treatment.

Authors:  M Turcani; H Rupp
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  Early postnatal changes in sarcoplasmic reticulum calcium transport function in spontaneously hypertensive rats.

Authors:  N Freestone; J Singh; E G Krause; R Vetter
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

8.  Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan.

Authors:  M Turcani; H Rupp
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

9.  Differential influence of fasting and BM13.907 treatment on growth and phenotype of pressure overloaded rat heart.

Authors:  H Rupp; V Elimban; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

Review 10.  Mechanisms of alterations in cardiac membrane Ca2+ transport due to excess catecholamines.

Authors:  K S Dhalla; H Rupp; R E Beamish; N S Dhalla
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.